Health Canada named in class action lawsuit

Eggertson, Laura
July 2010
CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, p1026
Academic Journal
The article reports that Health Canada was also named in the class-action lawsuits filed against GlaxoSmithKline (GSK) by the Merchant Law Group in Canada. It says that the lawsuits accuse that Health Canada fails to protect the public from the serious adverse medical effects of the medication using the type two diabetes drug rosiglitazone Avandia®. However, the court has not yet certified as a class-action lawsuit and none of the claims have been proven.


Related Articles

  • Rosiglitazone use and associated adverse event rates in Canada: an updated analysis. Iczkovitz, Sandra; Dhalla, Daniella; Ross Terres, Jorge A. // BMC Research Notes;9/30/2015, Vol. 8 Issue 1, p1 

    Background: We previously reported on the change in the use of rosiglitazone-containing products (RCP) and adverse event reporting rates in Canadian patients between 2004 and 2010. The present study extends this analysis to include the January 2011 to December 2012 time period. Methods: RCP...

  • Licensing drugs for diabetes. Lehman, Richard; Yudkin, John S.; Krumholz, Harlan M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/11/2010, Vol. 341 Issue 7772, p513 

    The authors call on regulatory agencies to require manufacturers of new drugs to provide definite evidence of greater benefits of their products than harm to patients. They cite the controversy over the safety of the diabetes drug rosiglitazone (Avandia) as an example of the failure of...

  • Rosiglitazone.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p81 

    The article describes the case of a 76-year-old man who developed proptosis during treatment with rosiglitazone for type 2 diabetes mellitus. He had persistent and progressive bilateral oedema of his upper and lower eyelids. Other medications being taken by the man include metformin and...

  • EU reps shed some light on rosiglitazone saga.  // Reactions Weekly;12/18/2010, Issue 1332, p6 

    The article focuses on the debate surrounding the initial approval, and eventual elimination, of the type 2 diabetes drug rosiglitazone in Europe in 2010. It references an article published in the October 22, 2010 issue of the journal "Diabetologia." Reported side effect of the drug was...

  • What can we learn from the continuing regulatory focus on the thiazolidinediones? FREEMANTLE, NICK // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/11/2010, Vol. 341 Issue 7772, p535 

    The author reflects on the controversy over the side effects of the diabetes drug rosiglitazone. He argues that in the case of rosiglitazone, several players such as sponsors, investigators, and journal editors seem to have been content to accept poor standards of methodological quality. He...

  • US parents take government to court over MMR vaccine claims. Dyer, Clare // BMJ: British Medical Journal (International Edition);6/16/2007, Vol. 334 Issue 7606, p1241 

    This article looks at efforts of parents in the U.S. and in Great Britain to link the measles, mumps and rubella (MMR) vaccine with autism in their children. In Great Britain, lawsuits against the manufacturer GlaxoSmithKline have been stopped by a lack of funding from the Legal Services...

  • Researcher urges Health Canada to suspend "unethical" diabetes drug trial. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;7/13/2010, Vol. 182 Issue 10, pE445 

    The article reports on the initiative of Canadian medical researchers which urge Health Canada to suspend the unethical trial for type 2 diabetes drug rosiglitazone. It relates that a safety alert has been issued by the U.S. Food and Drug Administration in 2007 concerning the possible...

  • Antibacterials/insulin detemir/omeprazole interaction.  // Reactions Weekly;8/1/2013, Issue 1463, p9 

    The article presents a case study of an 82-year-old man with hypoglycaemia, which developed during treatment with amoxicillin, clarithromycin, omeprazole and insulin detemir for type 2 diabetes.

  • WHEN TO SAY NO TO THIS DRUG. Harrar, Sari; L.T. // Prevention;Aug2002, Vol. 54 Issue 8, p146 

    Reports on the serious and potentially life-threatening side effect, lactic acidosis, that can result from taking metformin, a drug used to treat type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics